Phase 3 Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are 18 years old or older
- You have been formally diagnosed with multiple myeloma based on recognised diagnostic standards
- Your myeloma can be measured through specific blood or urine tests showing certain protein levels above set thresholds (confirm with trial site)
- Your myeloma has gotten worse during or after your most recent treatment, and if you have only had one previous treatment, your disease must have progressed within a specific time window after a stem cell transplant or after starting initial therapy (confirm with trial site)
- You have received between 1 and 3 previous lines of treatment, including specific types of myeloma drugs known as an IMiD and either a PI or a CD38 antibody, with at least 2 full cycles completed for each line unless your disease got worse right away
- You are eligible to receive at least one of four specific standard treatment combinations as decided by the trial doctor (confirm with trial site)
- You are generally well enough to carry out light daily activities with no or minimal limitations (a score of 0 or 1 on a standard health scale)
- Your blood counts and organ function (including blood cells, liver, and kidneys) meet minimum health thresholds as shown by recent lab tests (confirm with trial site)
Who may not be able to join:
- Your myeloma has spread to the brain or spinal fluid, or you have signs of this
- You have been diagnosed with certain related blood or protein disorders, such as primary amyloidosis, plasma cell leukaemia, Waldenstrom macroglobulinemia, or POEMS syndrome
- Your myeloma never responded to any previous treatment at all
- You have a significant neurological or psychiatric condition
- You have another serious medical condition that could put you at unacceptable risk from the trial treatment
- You have previously received any treatment that targets a protein called BCMA
- You have previously received a type of immune cell therapy called CAR-T or CAR-NK therapy
- You have previously received a type of therapy called a T-cell engager
- You received a donor stem cell transplant at any point, or received your own stem cell transplant within 12 weeks of joining the trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 1-877-240-9479
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
7 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
To demonstrate the superiority of AZD0120 relative to standard therapy (DKd, DPd, PVd, or Kd) by assessment of PFS in participants with RRMM.; To demonstrate the superiority of AZD0120 relative to standard therapy (DKd, DPd, PVd, or Kd) by assessment of MRD negativity rate at 9 months in participants with RRMM.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.